Company Overview and News

 
Mercantile increases Bauxite bid

2018-01-19 businessnews.com.au
Sir Ron Brierley-chaired Mercantile Investment Company has increased its bid for Perth-based mining company Bauxite Resources to 11 cents, putting it within the price range set out in the independent expert’s report.

 
Marcventures gets SEC go-signal to hike capital

2018-01-02 philstar
MANILA, Philippines — The Securities and Exchange Commission has approved the increase in authorized capital stock of listed Marcventures Holdings Inc. from P2 billion to P4 billion.

 
Bauxite Resources officially responds to Mercantile takeover bid

2017-11-17 australianmining.com.au
On November 8, Mercantile announced it was attempting to make a takeover bid for half of its unowned shares in Bauxite Resources. Mercantile had expressed displeasure at the slow pace of progress of Bauxite’s ventures as a primary reason for the bid.

 
Mercantile bidding for ‘ominous’ Bauxite in share takeover

2017-11-08 australianmining.com.au
Mercantile OFM, a subsidiary of Mercantile Investment Company, has announced its intentions to make an off-market takeover bid for half of all Bauxite Resources shares it doesn’t own at an offer price of $0.09 a share.

 
Marcventures buys outlone Philippines bauxite miner

2017-06-07 philstar
MANILA, Philippines - Marcventures Holdings Inc. and Asia Pilot Mining Philippines Corp. have entered into a term sheet that will finalize their merger.

 
Lopez’s crackdown on mines continues to rattle investors

2017-02-15 newsinfo.inquirer.net
An open gold-copper mining pit of OceanaGold in Kasibu, Nueva Vizcaya province. (PHOTO BY RICHARD BALONGLONG / INQUIRER NORTHERN LUZON)

 
Growth Opportunities in the Global Aluminum Door and Window Market

2017-01-09 prnewswire
NEW YORK, Jan. 9, 2017 /PRNewswire/ -- Trends, opportunities and forecast in this market to 2021 by product type (aluminum door [exterior door, patio door, others], aluminum window [sliding window, bi-fold window, others]), by end use type (residential, commercial [healthcare, education, hospitality, retail, office, other]), by region (North America, Europe, Asia Pacific, Rest of the World) The future of the global aluminum door and window market looks promising, with opportunities in the growth of the residential and commercial construction industry.

 
Triton Minerals Ltd appoints Peter Canterbury as managing director

2016-09-20 proactiveinvestors.com.au
Triton Minerals Ltd (ASX:TON) is focussed on graphite exploration and development of its advanced graphite development projects in Mozambique.

 
Bauxite secures lithium licence

2016-05-25 news.theage.com.au
JavaScript disabled. Please enable JavaScript to use My News, My Clippings, My Comments and user settings.

 
Bauxite secures lithium licence

2016-05-25 news.smh.com.au
JavaScript disabled. Please enable JavaScript to use My News, My Clippings, My Comments and user settings.

 
Bauxite Resources Ltd adds lithium play in WA hotspot

2016-05-25 proactiveinvestors.com.au
Bauxite Resources Ltd (ASX:BAU) has secured an exploration licence between Ravensthorpe and Esperance on ground that could be prosective for lithium, wedged between Pioneer Resources Ltd’s (ASX:PIO) recently pegged leases to the east and Metalicity Ltd’s (ASX:MCT) tenement to the west. It is also 120 kilometres east of Galaxy Resources Ltd’s (ASX:GXY) Mt Cattlin Lithium Mine in Western Australia. The company’s tenements have similarities to the nearby projects, with stream sediment sample taken in the south of the tenement by Geoscience Australia returning an elevated lithium value.

 
Update - Return of Capital - BAU

2016-05-11 asx.com.au

 
Return of Capital - BAU

2016-05-10 asx.com.au

Related Articles

HRTX : Heron Therapeutics Analysis and Research Report

2018-05-25 - Asif

Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...

ACIA: Acacia Communications Analysis and Research Report

2018-05-25 - Asif

Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...